SI-BONE, Inc. (NASDAQ:SIBN) CEO Sells $90,737.92 in Stock

SI-BONE, Inc. (NASDAQ:SIBNGet Rating) CEO Laura Francis sold 5,248 shares of the stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $17.29, for a total transaction of $90,737.92. Following the completion of the sale, the chief executive officer now directly owns 326,147 shares of the company’s stock, valued at approximately $5,639,081.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

SI-BONE Stock Performance

SIBN traded down $0.14 during trading hours on Wednesday, hitting $17.40. 389,536 shares of the stock were exchanged, compared to its average volume of 263,433. The stock has a 50-day simple moving average of $14.25 and a 200-day simple moving average of $17.34. SI-BONE, Inc. has a 12 month low of $11.89 and a 12 month high of $25.41. The stock has a market cap of $589.58 million, a price-to-earnings ratio of -8.83 and a beta of 1.35. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.90 and a quick ratio of 7.91.

SI-BONE (NASDAQ:SIBNGet Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.05). SI-BONE had a negative return on equity of 51.84% and a negative net margin of 69.36%. During the same period in the prior year, the firm earned ($0.42) EPS. Analysts anticipate that SI-BONE, Inc. will post -1.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Truist Financial decreased their price target on shares of SI-BONE to $17.00 in a research report on Friday, July 22nd. Morgan Stanley raised their price target on shares of SI-BONE from $18.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. JMP Securities reissued a “buy” rating and set a $36.00 price target on shares of SI-BONE in a research report on Wednesday, June 1st. Canaccord Genuity Group decreased their price target on shares of SI-BONE from $32.00 to $25.00 in a research report on Tuesday, May 10th. Finally, Needham & Company LLC decreased their price target on shares of SI-BONE from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Tuesday, August 9th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $27.57.

Institutional Investors Weigh In On SI-BONE

A number of hedge funds have recently added to or reduced their stakes in SIBN. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in SI-BONE by 111.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,141 shares of the company’s stock valued at $94,000 after buying an additional 3,769 shares during the last quarter. Amalgamated Bank bought a new stake in SI-BONE in the first quarter valued at $120,000. AQR Capital Management LLC bought a new stake in SI-BONE in the second quarter valued at $157,000. BNP Paribas Arbitrage SA lifted its stake in SI-BONE by 19.2% in the fourth quarter. BNP Paribas Arbitrage SA now owns 7,139 shares of the company’s stock valued at $159,000 after buying an additional 1,148 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in SI-BONE by 15.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 12,949 shares of the company’s stock valued at $171,000 after buying an additional 1,712 shares during the last quarter. 99.36% of the stock is currently owned by institutional investors.

About SI-BONE

(Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Featured Stories

Insider Buying and Selling by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.